Liquid blood tests to predict endometrial cancer return
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial studies whether blood “liquid biopsies” and tumor genetic testing can help predict whether endometrial cancer will come back after treatment. Results may help doctors plan follow-up and additional care based on a person’s recurrence risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older
- You have been diagnosed with endometrial cancer based on tissue testing
- You are scheduled for initial surgery, or you recently had your first surgery
- You can and will sign informed consent
- You have not had chemotherapy or radiation for endometrial cancer before joining
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for “methylated DNA markers” (special DNA patterns) to help detect endometrial, ovarian, and cervical cancers, and to support doctors around planned procedures. It may help find cancer earlier or better sort out who needs closer treatment.
This trial studies tumor DNA in blood and tissue from people with aggressive endometrial cancer to better understand the disease. You donate samples during surgery and follow-up visits.
This trial tests whether a blood test for ctDNA (cancer DNA fragments) can help doctors decide if standard chemotherapy plus an immunotherapy drug is working for people with advanced or recurrent endometrial cancer. It may help tailor your treatment based on how the cancer responds.
This study uses two simple tests (a cell sample from the uterus and a cervical DNA test) to find endometrial cancer early and to check how well fertility-sparing treatment is working.
This trial tests if a special blood test (called minimal residual disease testing) can find leftover cancer cells early in people with endometrial or cervical cancer. The goal is to see if this test can detect a return of cancer sooner than standard scans or exams.
This study looks at how well a surgical tool is used during standard surgery for early endometrial cancer, and whether it relates to test results from fluid taken in the abdomen. It may help surgeons improve how samples are collected and interpreted during routine care.
Hear when a new Endometrial Clear Cell Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.